Summit Therapeutics company profile
Company profile
Summit Therapeutics has 265 employees and is headquartered in Miami, United States.
Its products are marketed in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Its most advanced candidate, ivonescimab, is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis activity, and it is being studied for non-small cell lung cancer and colorectal cancer. The company is also testing the antibody in combination with chemotherapy in phase III trials, including in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC and in first-line unresectable metastatic colorectal cancer.
Summit Therapeutics was founded in 2003 and is headquartered in Miami, Florida, where it employs 265 people. For the fiscal year ended 31 December 2025, the company reported a net loss of USD 1.1 billion, or about USD 1,079.6 million.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 601 Brickell Key Drive, 33131, Miami
- Employees
- 265
- Chief executive
- Robert W. Duggan
- Founded
- 2003
- Fiscal year
- January - December
- Listing
- SMMT · NASDAQ
- Currency
- USD
- ISIN
- US86627T1088
- Website
- smmttx.com
Summit Therapeutics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| Halozyme TherapeuticsHALO | United States | $14.67B | 423 | 56.8% | 38.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
